var data={"title":"Sodium stibogluconate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium stibogluconate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243661?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium stibogluconate (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48895080\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiprotozoal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894731\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosage is expressed as mg of pentavalent antimony.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis: </b>IM, IV: 20 mg/kg/day. Duration of therapy is 20 days for cutaneous leishmaniasis and 28 days for mucosal and visceral leishmaniasis (CDC 2016a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894732\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Leishmaniasis: </b>IM, IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894733\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894734\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use in significant impairment (McCarthy 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894735\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Avoid use (WHO 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22785866\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, Solution, as sodium: Equivalent to 100 mg of pentavalent antimony/mL (30 mL, 100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894711\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium stibogluconate is not commercially available in the US; it is available for the treatment of leprosy through the Centers for Disease Control (CDC) Drug Service for patients that meet the eligibility criteria in the Investigational New Drug (IND) protocol. Contact the CDC Drug Service at 404-639-3670 or drugservice@cdc.gov. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=109944\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894737\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM, IV: Administer IM or IV (preferred) over 5 to 10 minutes; IM injection may be painful because volume per dose may be large (CDC 2016a; McCarthy 2015; WHO 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894713\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Leishmaniasis:</b> Treatment of cutaneous, mucosal, and visceral leishmaniasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49629439\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Diarrhea (&le;2%), nausea (&le;2%), vomiting (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flattened T wave on ECG, inversion T wave on ECG, prolonged Q-T interval on ECG</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache, lethargy, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased amylase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, anorexia, increased serum lipase (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Change in platelet count (decreased; transient), decreased hemoglobin (transient), decreased white blood cell count (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (transient), pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Diaphoresis, facial flushing, fever, hemorrhage (from nose or gums), jaundice, pancreatitis, rigors, skin rash, substernal pain, vertigo, wound healing impairment (cheek lesion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894717\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: ECG changes, including T-wave inversion, prolonged QT interval, and arrhythmia may occur and appear to be dose and duration dependent. Cardiotoxicity and sudden death have been reported (rare). Discontinue immediately if prolongation of a corrected QT interval &gt;0.5 seconds or other signs of cardiotoxicity (eg, significant arrhythmia, concave ST segments) occur. (Herwaldt 1992; WHO 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Anemia, leukopenia, and thrombocytopenia may occur during treatment; periodically monitor CBC. If possible, iron deficiency should be corrected prior to therapy initiation (WHO 1995; WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevated liver enzymes may occur; periodically monitor LFTs. Discontinue use if hepatotoxicity occurs (WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal effects: Arthralgias and myalgias, sometimes severe and persisting for weeks after treatment, may occur (McCarthy 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Pancreatic enzyme elevations are common; pancreatitis is less common but may occur. Avoid use in patients with preexisting pancreatic disease (WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Avoid use in patients with preexisting cardiac disease (WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with preexisting hepatic disease (WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use is not recommended in patients with significant renal impairment (McCarthy 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients of advanced age are at higher risk for toxicity-related mortality; use with caution (WHO 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283991\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283988\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109944&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the cardiotoxic effect of Sodium Stibogluconate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B (Conventional): May enhance the cardiotoxic effect of Sodium Stibogluconate. Specifically, arrhythmia and sudden cardiac death risks may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894714\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of sodium stibogluconate in pregnancy has been described; however, the risk of spontaneous abortion may be increased in comparison to use of other agents (Mueller 2006). Untreated leishmaniasis may also lead to spontaneous abortion, as well as babies born small for gestational age and congenital leishmaniasis (WHO 2010). Pregnancy may activate previous maternal infection (Meinecke 1999). Maternal infection is likely transmitted to the baby during delivery (Meinecke 1999; Mescouto-Borges 2013). Lesions observed in cutaneous leishmaniasis may be larger in pregnant women (Morgan 2007). Other agents are recommended for the treatment of visceral leishmaniasis in pregnant women (Mueller 2006; WHO 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894715\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium stibogluconate is excreted in breast milk (Berman 1989).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894730\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">A protein-rich diet is recommended during therapy (WHO 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894740\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and weekly EKG, serum creatinine, liver function tests, serum amylase, and CBC; patients requiring &gt;20 days of treatment should begin twice-weekly EKG monitoring during week 3 of therapy; twice-weekly or more frequent EKG monitoring may be indicated in certain patients (eg, elderly, underlying cardiac, renal, or hepatic disease) (Herwaldt 1992; McCarthy 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894725\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exact mechanism of action is unknown. Proposed mechanisms include conversion to trivalent form of antimony that affects glucose metabolism, fatty acid beta oxidation, and adenosine triphosphate (ATP) formation; forms a complex with adenine nucleosides, acting as an inhibitor of <i>Leishmania</i> purine transporters or interfere with purine salvage pathway; and activation of host immune system (McCarthy 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48894726\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Well absorbed (McCarthy 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~10 hours (McCarthy 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% as unchanged drug [over 6 hours]) (WHO 1995)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22786584\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pentostam (AE, EG, GB, IL, JO, KW, QA, SA, SI);</li>\n      <li>Stibovita (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berman JD, Melby PK, Neva FA. Concentration of Pentosam in human breast milk. <i>Trans R Soc Trop Med Hyg</i>. 1989;83(6);784-785.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/2559511/pubmed\" target=\"_blank\" id=\"2559511\">2559511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC)a. Leishmaniasis&mdash;Resources for Health Professionals. <a href=\"http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl\" target=\"_blank\">http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl</a>. Updated August 8, 2016. Accessed August 11, 2016a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC)b. CDC Drug Service&mdash;Our Formulary. <a href=\"http://www.cdc.gov/laboratory/drugservice/formulary.html\" target=\"_blank\">http://www.cdc.gov/laboratory/drugservice/formulary.html</a>. Updated March 9, 2016. Accessed August 8, 2016b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinentclinical studies. <i>Am J Trop Med. Hyg</i>. 1992;46(3):296-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/1313656/pubmed\" target=\"_blank\" id=\"1313656\">1313656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCarthy JS, Wortmann GW, Kirchhoff LV. Drugs for protozoal infections other than malaria. In: Bennett JE, Dolin R, and Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 8th ed. Philadelphia, PA: Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. <i>Pediatrics</i>. 1999;104(5):e65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/10545591/pubmed\" target=\"_blank\" id=\"10545591\">10545591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mescouto-Borges MR, Mau&eacute;s &Eacute;, Costa DL, et al. Congenitally transmitted visceral leishmaniasis: report of two Brazilian human cases. <i>Braz J Infect Dis</i>. 2013;17(2):263-266. doi: 10.1016/j.bjid.2012.10.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/23453409/pubmed\" target=\"_blank\" id=\"23453409\">23453409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. <i>Clin Infect Dis</i>. 2007;45(4):478-482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/17638198/pubmed\" target=\"_blank\" id=\"17638198\">17638198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. <i>J Antimicrob Chemother</i>. 2006;58(4):811-815.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/16916865/pubmed\" target=\"_blank\" id=\"16916865\">16916865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO Technical Report Series: 949. Geneva, Switzerland: March 22-26, 2010.http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Model Prescribing Information. Drugs Used in Parasitic Diseases-Second Edition. Geneva, Switzerland: World Health Organization; 1995. http://apps.who.int/medicinedocs/en/d/Jh2922e/.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109944 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F48895080\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F48894731\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F48894732\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F48894733\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F48894734\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F48894735\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22785866\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F48894711\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F48894737\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F48894713\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49629439\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F48894717\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46283991\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46283988\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F48894714\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F48894715\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F48894730\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F48894740\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F48894725\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F48894726\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22786584\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/109944|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Sodium stibogluconate (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}